Advanced searches left 3/3

Alzheimer's Disease - PubMed

Summarized by Plex Scholar
Last Updated: 14 May 2022

* If you want to update the article please login/register

Prevent Drug Leakage via the Boronic Acid Glucose-Insensitive Micelle for Alzheimer's Disease Combination Treatment.

BA materials used in diabetes management have shown improved results in a high-glucose environment than average. In comparison, the concentration of glucose in the brain is much lower than that in AD patients' blood. Hence, in AD, the common glucose and oxidative stress dual-sensitive BA materials will eventually experience drug leakage. On senescence-prone mouse prone 8 mice, the treatment effect and the drug-loaded GIM micelle's synergism mechanism were investigated.

Source link: https://doi.org/10.1021/acsami.2c03684


Alzheimer's Disease Prevention Health Coaching.

Alzheimer's disease prevention at the community level is considered to be highly beneficial in reducing Alzheimer's disease. In 2019-2020, Diverse older adults living in Richmond, VA, with incomes below $12,000/year and monitoring diabetic/cardiovascular disease were included in weekly lifestyle telephone health education for 12-weeks. The health coaching sessions were designed to offer AD lifestyle risk reduction training, target setting, and assistance: encouragement and self-efficacy. Consequently, n=30 of the original sample's cohort also agreed to continued health education during the 2020-2021 COVID-19 pandemic. Measures that have been repeated ANOVAs were conducted to investigate Time and Date*Memory Status effects.

Source link: https://doi.org/10.14283/jpad.2022.33


Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report.

As shown in a biomarker profile, a personalized strategy that takes into account the genetic and acquired causes of AD in any given individual as well as their age of disease may vary.

Source link: https://doi.org/10.14283/jpad.2022.29


Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy.

Amyloid-related imaging abnormalities are among the adverse events reported in Alzheimer's disease trials of anti-amyloid beta therapies. Both the cerebral parenchyma and vaping cultures are unclear, but it may be attributed to antibodies binding to accumulated A in both the cerebral parenchyma and vasculature, resulting in decreased vessel wall strength and increased leakage into surrounding tissues. ARIA-E is classified as vasogenic edema in the brain parenchyma or sulci's leptomeninges/sulci, according to radiologists, while ARIA-H is hemosiderin deposits that appear as microhemorrhages or superficial siderosis. ARIA's temporary suspension of therapy has been used in clinical trials, as well as permanent or intermittent discontinuation of therapy until symptoms or radiographic signs of ARIA are clear. ARIA largely recovers without concomitant therapy, and there are no reliable studies on potential treatments for ARIA. Given the availability of an anti-A therapy, ARIA monitoring will now be included in routine clinical practice.

Source link: https://doi.org/10.14283/jpad.2022.21


A Maitake (Grifola frondosa) polysaccharide ameliorates Alzheimer's disease-like pathology and cognitive impairments by enhancing microglial amyloid-β clearance.

In the current study, the results indicated that PGM could improve learning and memory impairment, attenuate neuron loss, and histopathological abnormalities in APP/PS1 mice. In addition, PGM treatment may cause microglia and astrocyte formation to the A plaques and promote microglial recruitment. In addition, PGM could increase A phagocytosis, thereby minimizing A burden and the pathological changes in APP/PS1 mice's cortex and hippocampus. These results showed that PGM administration could cause memory impairment by immunomodulatory intervention, and that dietary supplementation with PGM may have potential benefits on brain aging memory dysfunction.

Source link: https://doi.org/10.1039/c9ra08245j


Dapsone is an anticatalysis for Alzheimer's disease exacerbation.

Patients with leprosy and AD were included in our analysis. DDS recommended AD diagnosis, T3 DDS unprescribed AD diagnosis, and T 4: DDS undiagnosed AD undiagnosed were among the four groups identified. According to dapsone presence or absence, there can be a clear distinction on AD. The prevalence of AD without dapsone was also high without T2:T3. T3:T3 was found that the incidence of AD was significantly higher without dapsone. According to our report, dapsone can prevent AD exacerbation and may be a preventive therapeutic option for exacerbated AD.

Source link: https://doi.org/10.1016/j.isci.2022.104274


A time-of-flight mass spectrometry based strategy to fast screen triterpenoids in Xanthoceras sorbifolia Bunge husks for bioactive substances against Alzheimer's disease.

Bunge, Xanthoceras sorbifolia Bunge, is a Chinese folk medicine. To characterize the barrigenol type triterpenoids in the husks and dosed rat plasma, an effective and cost-effective approach based on high resolution mass spectra mixed with various data mining techniques was developed. To reveal more bioactive compounds, an effective and practical approach based on high resolution mass spectra combined with multiple data mining techniques was used. This research will be a useful resource of the bioactive components in Xanthoceras sorbifolia Bunge husks against Alzheimer's disease, and the suggested approach can also be applied to the discovery of the active constituents in other drugs.

Source link: https://doi.org/10.1039/c8ra01765d


Current progress, challenges and future prospects of diagnostic and therapeutic interventions in Alzheimer's disease.

The pathophysiological hallmarks of AD are extracellular senile plaques of amyloid beta and intracellular neurofibrillary tangles of phosphorylated Tau in the brain. Multiple hypotheses based on pathophysiological changes that occur during AD's onset and progression have been suggested in an attempt to clarify the complexity and multifactorial nature of AD. Nonetheless, the amyloid hypothesis is the most widely accepted and is closely linked to AD disease signs that span both disease hypotheses. Hence, amyloid plaques are excellent biomarkers for the initiation of an early diagnosis of AD. In addition, the initiation of amyloid plaques can also be a target for the development of therapeutic drugs by an inclusive strategy that considers multiple disease pathways involved in AD.

Source link: https://doi.org/10.1039/c8ra03620a


Blood-based immunoassay of tau proteins for early diagnosis of Alzheimer's disease using surface plasmon resonance fiber sensors.

Using surface plasmon resonance fiber technology, we present the immunoassay of tau proteins in human serum. Both total tau and phosphorylated tau protein levels were significantly higher in AD patients' sperm and phosphorylated tau proteins on an annual basis, according to our results. The detection of total tau and phosphorylated tau proteins in 2. 4 pg mL-1 and 1. 6 pg mL-1 were within acceptable limits, according to respectively. The AD group had an average concentration of total tau proteins 6-fold higher than the control group, but the concentration of phosphorylated tau proteins was 3-fold higher than that of the control group. This inhomogeneity between both types of tau proteins is more likely to be produced in blood than phosphorylated tau proteins, which may be one of the potential key elements in AD progress.

Source link: https://doi.org/10.1039/c7ra11637c

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions